A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)

Inclusion Criteria: * Age \>18 * Histological or cytological diagnosis of adeno- or undifferentiated non-small cell carcinoma of pancreas. * Considered to be unresectable based on following: extensive peri-pancreatic lymph node involvement, encasement or occlusion of the SMV or SMV/portal vein confluence, direct involvement of SMA, coeliac axis, inferior vena cava or aorta. * Performance status 0-2 * No evidence of metastatic disease as determined by CT scan/ other investigations * Adequate bone marrow function with platelets\>100\^9/l; WBC\>3x10\^9/l;neutrophils\> 1.5x10\^9/l * Serum bilirubin ,1.5 x ULN and transaminases \< 2.5 x ULN * Calculated/measured GFR \>50ml/min * No concurrent uncontrolled medical condition * No active malignant disease other than non-melanotic skin cancer or carcinoma in situ of the uterine cervix over the last 10 years * Life expectancy \> 3months * Adequate contraceptive precautions * Informed written consent Exclusion Criteria: * medical or psychiatric conditions that compromise the patient's ability to give informed consent * Presence of met. disease * Concurrent uncontrolled medical conditions * Any previous chemo/RT or any investigational treatment for advanced pancreatic cancer. * Adjuvant chemo + fluoropyrimidine or gemcitabine within 12months of trial entry * Adjuvant RT with/without chemo for pancreatic cancer. * Pregnancy/breast feeding * Patients with known malabsorption syndromes ro a lack of physical treatment of the upper GI tract. * Patients with a known hypersensitivity to 5-FU or with a DPD deficiency. * Clinically significant CVD